A conference presented by the Royal Women’s Hospital
|
|
|
14th October 2010 - Bio21 Institute, 30 Flemington Road, Parkville, Victoria
|
| Topics covered will include:
|
| - HPV vaccines
- HPV DNA testing
- Changes & progress in cervical cytology screening
- Anal cancer and potential screening
- Oropharyngeal cancers
|
|
|
| |
|
|
 |
Speakers
|
|
|
The venue for all sessions is the Bio21 institute, 30 Flemington Road, Parkville Victoria.
|
|  |  | (pdf 159kb)
|
|
|
|
|
|
|
Program for Thursday 14th October
| | | | Welcome and program introduction
|
|
|
| | Session 1 – HPV vaccines – what are the indications for males?
|
| Chair: Professor Suzanne Garland
|
|
| | Anal cancer – what do we know, should we be screening and how?
| Associate Professor Richard Hillman
|
| | What is the latest data on men from the phase 3 HPV vaccine clinical trials?
| Professor Joel Palefsky
|
| | The epidemiology of anal cancer in Australia: implications for the development of anal cancer prevention services
| Professor Andrew Grulich
|
| | Vaccine efficacy against genital warts in Australia
| Professor Christopher Fairley
|
|
|
| | | | | Psychological impact of screening for cervical cancer or HPV infection
| Dr Marie Pirotta
|
| | What is modelling telling us about vaccination of males?
| Dr Jane Hocking
|
| | |
|
| | | Chair: Professor Marion Pitts
|
|
| | How we best talk to males about HPV and HPV vaccines?
| Professor Marian Pitts
|
| | HPV vaccination in general practice: Where to now?
| Associate Professor Danielle Mazza
|
| | What is the end of study data for the bivalent and quadrivalent vaccines?
| Dr Jeffrey Tan
|
| | |
|
| | | | Session 3 – Oropharyngeal
|
| Chair: Dr Julia Brotherton
|
|
| | HPV: a new type of oropharyngeal cancer
| Dr Tim Iseli
|
| | Recurrent respiratory papillomatosis, HPV and vaccination
| Dr Daniel Novakovic
|
| | Oropharyngeal cancers– Australian data
| Dr Angela Hong
|
| | |
|
| | | | Session 4 – Vaccines and screening in the vaccine era
|
| |
| | Australian HPV genotype prevalence, the WHINURS data
| Professor Suzanne Garland
|
| | How might cervical screening change in the future?
| Associate Professor Marion Saville
|
| | HPV vaccination coverage in Australia: achievements and challenges
| Dr Julia Brotherton
|
| | Management of HPV and HIV/ vaccination of HIV (+)
| Professor Joel Palefsky
|
|
|
| Session 5 – Q&A/ask the expert session
|
| Chair: Professor Suzanne Garland
|
| 5.10pm - 6.00pm All Speakers
|
|
|
| |
|
|
 |
|
Professor Joel Palefsky
| Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine at the University of California San Francisco School of Medicine.
Prof Palefsky completed his undergraduate medical training and training in Internal Medicine at McGill University and completed his fellowship in Infectious Diseases at Stanford University in 1989. He then joined the faculty at the University of California, San Francisco, where he remains to this day.
He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the Director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic at the UCSF Cancer Center.
He has pioneered diagnostic and treatment methods for anal intraepithelial neoplasia (AIN) and has been an advocate for screening and treatment of AIN in high-risk populations to prevent anal cancer. He is the chair of the HPV Working Group of the U.S. National Cancer Institute-supported AIDS Malignancy Consortium.
Prof Palefsky is the leader of the Pathways to Careers in Clinical and Translational Research program at the University of California San Francisco, a program designed to train medical and allied health sciences students in the skills needed to pursue careers in clinical and translational research. He is a member of the board of the American Society for Colposcopy and Cervical Pathology (ASCCP) and co-chair of the ASCCP Special Populations Working Group. He is the author of over 220 publications.
|
|
|
|
|
